Please try another search
The Sub-fund's principal investment objective is to provide long-term capital appreciation in SEK. The Sub-fund seeks to achieve its objective by investing principally 90% of its total assets in transferable equity and/or equity-related securities of healthcare and medical services and product companies worldwide. Investments will be in the named securities of producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies. Such equity or equity-related securities may include common or preferred stock, depository receipts, warrants.
Name | Title | Since | Until |
---|---|---|---|
Dani Saurymper | - | 2016 | Now |
Biography | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review